Are self-tests really reliable enough to trust? In July 2025, a major study from the University of Birmingham raised some interesting questions about the safety, accuracy, and marketing of self-test kits available in the UK. This research, published in The BMJ, examined 30 at-home health tests and argued that many of them lacked sufficient evidence to support their claims or had usability problems that could impact their effectiveness (University of Birmingham, 2025).
At Berkeley Health, we appreciate and value this degree of scientific inquiry, as we believe that the self-testing industry should uphold high clinical and regulatory standards. When designed and used correctly, self-tests are an asset to individuals looking to take charge of their health. However, it is important to consider that not all tests available on the market provide the advanced accuracy and reliability required of a high quality self-testing product.
The Evolution of Trust in Self-Testing
When home pregnancy tests were introduced in the UK during the 1970s, they faced a fair amount of scepticism from both the public and the medical field. Many people questioned their accuracy and whether individuals could really test themselves reliably outside of a clinical environment. But over the years, through rigorous scientific validation, proper regulation, and effective public education, these tests have gained a reputation for being trustworthy. Today, they are not only widely accepted but also recommended by healthcare professionals, making them a vital part of personal healthcare.
While pregnancy tests and, more recently, COVID self-tests have made significant headway in gaining public understanding, the knowledge and acceptance of self-testing for other health conditions is still a work in progress. This underscores a crucial point: self-tests that are well-supported by evidence, appropriately regulated, and come with clear guidance can foster public confidence and complement traditional healthcare practices.
Our Commitment to Clinical-Grade Accuracy
Our portfolio includes a wide range of clinically validated self-tests covering infectious diseases, fertility, gastrointestinal health, drug use, and chronic conditions.
For instance, our prostate-specific antigen (PSA) test is a crucial screening tool for men aged 45 and over. Independent trials show it has 97.5 percent accuracy, with 100 percent sensitivity and 95 percent specificity. An elevated PSA level can be an indicator of prostate cancer and early detection of prostate cancer greatly improves treatment outcomes.
Similarly, our C-reactive protein (CRP) inflammation test achieves 98 percent accuracy. Each kit comes with clear, user-friendly instructions designed to minimise errors and build user familiarity and confidence.
We select our tests through a rigorous evaluation process, including independent clinical validation and ongoing quality control. Only tests that meet internationally recognised benchmarks for accuracy and safety are included in our range.
Our trusted tests are available through major high-street retailers and pharmacies, all of which maintain strict medical device acceptance criteria. Our products are produced in ISO-certified manufacturing environments and hold approvals from leading health authorities worldwide, including the MHRA (UK), CE marking (Europe), and health ministries in Saudi Arabia, the UAE, Bahrain, Australia, and many more.
Supporting the NHS: Understanding Challenges and Shared Responsibility
The NHS is currently under a lot of strain, grappling with increasing patient demand while resources remain tight. Statistics reveal that about 22.5 percent of cancer cases in England are diagnosed only after patients present in emergencies, often at a stage that leads to worse outcomes (NHS Digital, 2025). These delays are primarily due to systemic challenges like staffing shortages and limitations in diagnostic capacity, rather than mistakes made by individual clinicians.
Further statistics shed light on the severity of these issues: since 2015, nearly 382,000 patients in England have started cancer treatment later than the NHS’s 62-day target, which has a direct impact on survival rates (Cancer Research UK, 2024). Additionally, some audits indicate that stroke misdiagnosis occurs in 20 to 30 percent of emergency cases, complicating treatment (Smith et al., 2025).
Doctors, GPs, and hospitals operate in complex environments, making crucial decisions every day. These circumstances highlight the urgent need for improved diagnostic tools and increased patient engagement. Self-testing can play a valuable role alongside professional care, empowering individuals to monitor their health proactively. Self-testing can promote a more efficient and timely patient progression pathway, it promotes earlier medical consultations, helps cut down on unnecessary appointments, and aids the NHS in focusing on patients who need more urgent attention.
The Role of Self-Testing in Modern Healthcare and Public Health Goals
The NHS’s 10-Year Health Plan aims to shift care closer to communities, emphasising prevention, early diagnosis, and digital health innovations (NHS England, 2025).
Self-testing contributes to these goals by:
-
Reducing the strain on GPs by enabling people to manage minor or initial symptoms at home. For example, home blood glucose monitoring reduces hospital visits and allows timely treatment adjustments for diabetics (American Diabetes Association, 2024).
-
Supporting earlier detection of diseases like prostate cancer, which improves survival rates. Self-sampling for infections like chlamydia has increased screening by 30%, leading to better treatment outcomes and less spread (Public Health England, 2022).
-
Reaching populations less likely to attend routine checks, such as men aged 45 to 60, by offering private, accessible screening options. HIV self-testing has significantly boosted testing uptake in hard-to-reach groups, facilitating earlier diagnosis and prevention (Witzel et al., 2023).
-
Facilitating access to care via digital platforms, enabling users to receive timely advice and follow-up (NHS Digital, 2024). Our products support this vision where possible.
A recent Queen Mary University pilot showed that HPV self-sampling kits offered during GP visits could prevent about 1,000 cervical cancer cases annually, underscoring self-testing’s public health value (Queen Mary University London, 2025).
Partnering with Healthcare Professionals
We're grateful to have the backing of NHS GP and health educator Dr. Amir Khan, who openly supports our self-tests for their accuracy and user-friendliness. His endorsement truly reflects our dedication to offering products that enhance professional care.
Our partnerships span the UK and beyond, as we collaborate closely with top healthcare professionals, including consultant diagnosticians and health tech experts. These alliances are crucial in ensuring our products uphold high clinical standards and encourage safe, responsible self-testing.
Importantly, esteemed UK organisations like the Royal College of General Practitioners and the Royal College of Pathologists acknowledge the vital role of validated self-testing when carried out responsibly and with correct guidance.
Closing Thoughts
Self-testing is no longer a niche concept; it is steadily becoming a reliable part of the future of healthcare. With thorough validation, clear guidelines, and partnership with healthcare professionals, self-tests can empower individuals to take control of their health while effectively complementing traditional care.
As healthcare shifts towards prevention, digital integration, and a focus on community, self-testing provides practical solutions to ease the burden on health services and reach those who are often overlooked.
We encourage anyone thinking about self-testing to opt for clinically validated products and keep an open line of communication with healthcare professionals to ensure the best outcomes possible. By combining responsible innovation with patient empowerment, we can make self-testing a key element of proactive health management for years to come.